Gene therapy for vision loss: Long-Term safety check begins
NCT ID NCT01678872
Summary
This study is a long-term safety check for 18 patients who previously received an experimental gene therapy called RetinoStat for wet age-related macular degeneration, a leading cause of vision loss. The main goal is to monitor these patients for any long-term side effects after their initial treatment. It is a follow-up study and is not testing a new treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AGE-RELATED MACULAR DEGENERATION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
John Hopkins University Hospital
Baltimore, Maryland, 21287-9277, United States
-
Oregon Health & Science University
Portland, Oregon, 97239, United States
-
University of Iowa Hospitals & Clinics
Iowa City, Iowa, 52245, United States
Conditions
Explore the condition pages connected to this study.